Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$771.89K$771.89K+154.6% vs Q2 2017 Net Income-$7.54M-$7.54MN/M vs Q2 2017 EPS Diluted-$0.34-$0.34N/M vs Q2 2017 Operating Income-$6,831,001N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,714,136N/M Margins · derivedOperating margin-885.0%+1700.6 pt vs Q2 2017
Net margin-976.8%+1677.4 pt vs Q2 2017
ended Mar 31, 2018 · filed May 15, 2018 · 45 d after period end